全球的生物仿製藥市場分析 是由出版商RNCOS E-Services Pvt. Ltd.在2011年07月所出版的。
這份英文市場調查報告書包含65 Pages 價格從美金1400起跳。
全球的生物仿製藥業界在過去數年急遽成長中。醫療費用高漲、高齡化、醫療支出、高價藥劑等各種因素支撐著該業界的成長。全球的生物仿製藥市場預期在2010∼2015年將以CAGR52%擴大。
本報告，分析全球生物仿製藥市場的大範圍情報，彙整現在的市況、業界動向、競爭環境、今後數年的市場結構、產品的技術創新展望等，由下列摘要形式闡述。
第1章 分析師的觀點
第2章 調查方式
第3章 市場促進因子與阻礙因子
- 生技企業與藥廠合作致力於生物仿製藥的藥物設計
- 生物仿製藥的認可增加
- 生物學名藥：市場加入門檻
- 風險資本家的關注高漲
第4章 產業實績
- 市場規模
- 現在已上市的生物仿製藥
- 紅血球生成素
- 人類生長激素
- 重組人胰島素
- G-CSF
- 干擾素
第5章 地區別市場
第6章 法規環境
第7章 專利失效與產品認可
第8章 合作與收購
第9章 競爭情勢
- Teva
- Sandoz
- Hospira
- Mylan
- Actavis
- Biocon Ltd.
- Cipla Ltd.
- Dr. Reddy's Laboratories Ltd.
- Wockhardt Ltd.
圖表
Abstract
The global biosimilars industry has been growing stupendously since the past
few years. Various factors, such as increasing healthcare costs, burgeoning
aging population, high pharmaceutical expenditure, and costly drugs are
driving the incessant growth of the global biosimilars industry.
According to our new research report “Global Biosimilars Market
Analysis”, the global biosimilars market is anticipated to grow at a
CAGR of around 52% during 2010-2015. Market growth will be driven by upcoming
patent expiries and the rising drugs bill that will encourage payers to
address the barriers to biosimilars' access in order to control costs. As the
governments and private players have stepped in the industry across various
geographical locations, the future prospects of the market shows immense
opportunities to tap on.
Our thorough study on the industry indicates that the Global Biosimilars
industry has witnessed a number of product launches and mergers & acquisitions
in the past few years. The main focus of the companies has been to introduce
effective and quality products in the market so that it gains a worldwide
acceptance.
Our report has found that as far as number of biosimilars approvals is
concerned, Europe holds a numero uno position in the market. However, despite
having a specific regulatory patheways for biosimilars in the regions, a very
limited number of players have launched their products in this region.
On the competitive front, Sandoz is presently the global market leader in
biosimilars sales (the only company to have more than two biosimilar products
approved) with Teva and Hospira also developing a range of biosimilar
products. Meanwhile, some Indian companies are also using their experiences
within the deregulated markets to produce dossiers and products suited for the
regulated markets.
The report provides extensive information and rational analysis of the global
biosimilars market. It has thoroughly examined current market drivers and
restraints, industrial developments, and competitive landscapes to enable
clients understand the market structure and its progress in the coming years.
The report also provides an insight into different biosimilars marketed
products along with country-wise analysis to present an overview of the
developments taking place in the global biosimilars industry. Further, a
review of product introductions/innovations and recent industry activity has
also been covered in the report.
Table of Contents
1. Analyst View
2. Research Methodology
3. Market Drivers & Restraints
- 3.1. Biotech Allies with Pharma to Discover Biosimilars
- 3.2. Biosimilars Approvals are on the Rise
- 3.3. Biogenerics: Market Entry Barriers
- 3.4. Rising Interests of Venture Capitalists
4. Industry Performance
- 4.1. Market Size
- 4.2. Currently Marketed Biosimilars
- 4.2.1. Erythropoietin
- 4.2.2. Human Growth Hormone
- 4.2.3. Recombinant Human Insulin
- 4.2.4. G-CSF
- 4.2.5. Interferons
5. Major Geographical Market
- 5.1. Americas
- 5.1.1. US
- 5.1.2. Canada
- 5.1.3. Mexico
- 5.2. EU
- 5.3. Asia Pacific
- 5.3.1. Korea
- 5.3.2. China
- 5.3.3. India
6. Regulatory Environment
7. Patent Expirations & Product Approvals
8. Collaborations & Acquisitions
9. Competitive Landscape
- 9.1. Teva
- 9.2. Sandoz
- 9.3. Hospira
- 9.4. Mylan
- 9.5. Actavis
- 9.6. Biocon Ltd.
- 9.7. Cipla Ltd.
- 9.8. Dr. Reddy' s Laboratories Ltd.
- 9.9. Wockhardt Ltd.
List of Figures:
- Figure 4-1: Global - Biosimilars Market (Million US$), 2010 & 2015
- Figure 4-2: Global - Biosimilars Market by Segment (%), 2010
- Figure 4-3: Global - Forecast for Biosimilars Market by Segment (%), 2015
